Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.
about
Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement.
P2860
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Dose and plasma concentration ...... isease - clinical application.
@ast
Dose and plasma concentration ...... isease - clinical application.
@en
type
label
Dose and plasma concentration ...... isease - clinical application.
@ast
Dose and plasma concentration ...... isease - clinical application.
@en
prefLabel
Dose and plasma concentration ...... isease - clinical application.
@ast
Dose and plasma concentration ...... isease - clinical application.
@en
P2093
P2860
P356
P1476
Dose and plasma concentration ...... isease - clinical application.
@en
P2093
Asa K Wallin
Carina Wattmo
Erik Jedenius
P2860
P2888
P356
10.1186/ALZRT156
P407
P50
P577
2013-01-03T00:00:00Z
P5875
P6179
1021242846